Background and Objectives The purpose of this study was to investigate the apoptotic pathway, and the effect and mechanism of IGF-1 insulin like growth factor 1 as a therapeutic agent, in Adriamycin ADR induced cardiomyopathy. Materials and Methods We divided 17 mice into ADR n 6 , ADR IGF-1 n 6 and saline n 5 groups. The following were injected into the intraperitoneal cavity for the specified periods 2.5 mg/kg of ADR every week for 6 weeks, 0.1 mg/kg of IGF-1 in the 5th and 6th weeks and 10 mL/kg of saline every week for 6 weeks. Transthoracic echocardiography, with a 15MHz linear array, was performed before and after injection of the drugs. A TUNEL assay and immunohistochemical staining for Bax, bcl-2, capase-8 and 9, and western blotting for Bax and bcl-2 were performed on the myocardium. Results The fractional shortening decreased 38.5 3.2% before vs. 29.2 5.5% after, p 0.05 and the left ventricular end systolic dimension increased 2.5 0.3 mm before vs. 3.1 0.5 mm after, p 0.05 following the injection of the ADR, but there were no interval changes in the mice treated with saline or ADR IGF-1. The TUNEL assay showed a higher apoptotic index in the mice treated with ADR than in those treated with saline or ADR IGF-1 46 8% in ADR, 0.1 0.03% in control, 22 5% in ADR IGF-1, p 0.05 . The immunohistochemical staining and western blot showed an increase in the expression of Bax, and a decrease in the expression of bcl-2 in the mice treated with ADR than in those treated with ADR IGF-1 or saline. Conclusion The apoptosis caused by the increased expression of Bax, and the decreased expression of bcl-2, was an important pathogenetic mechanism, and the IGF-1 prevents the progression of cardiomyopathy by attenuating the expressions of Bax and bcl-2 in ADR induced cardiomyopaththy.

